{
  "source": "PA-Med-Nec-Vowst.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2310-3\nProgram Prior Authorization/Medical Necessity\nMedication Vowst™ (fecal microbiota spores, live-brpk)\nP&T Approval Date 7/2023, 12/2023, 12/2024\nEffective Date 3/1/2025\n1. Background:\nVowst is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in\nindividuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).\n2. Coverage Criteriaa:\nA. Authorization\n1. Vowst will be approved based on all of the following criteria:\na. Diagnosis of recurrent Clostridioides difficile infection (rCDI) as defined by both of\nthe following:\n(1) Presence of diarrhea defined as a passage of 3 or more loose bowel movements\nwithin a 24-hour period for 2 consecutive days\n(2) A positive stool test for Clostridioides difficile toxin\n-AND-\nb. Patient is 18 years of age or older\n-AND-\nc. Patient has had one or more recurrence(s) of CDI following an initial episode of\nCDI\n-AND-\nd. Patient has had a failure, contraindication, or intolerance to Rebyota for the\nprevention of rCDI\n-AND-\ne. Patient has completed at least 10 days of one of the following antibiotic therapies\nfor rCDI 2 to 4 days prior to initiating Vowst^:\n(1) Oral vancomycin\n(2) Dificid (fidaxomicin)\n-AND-\n© 2024 UnitedHealthcare Services Inc.\n1\nf. Previous episode of CDI is under control [e.g., less than 3 unformed/loose (i.e.,\nBristol Stool Scale type 6-7) stools/day for 2 consecutive days]\n-AND-\ng. Patient will drink magnesium citrate on the day before and at least 8 hours prior to\ntaking the first dose of Vowst\n-AND-\nh. Prescribed by or in consultation with one of the following:\n(1) Gastroenterologist\n(2) Infectious disease specialist\nAuthorization will be issued for 1 month\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n^Tried/failed al",
    "ply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n^Tried/failed alternative(s) are supported by FDA labeling.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may apply.\n4. References:\n1. Vowst [package insert]. Cambridge, MA: Seres Therapeutics, Inc.; June 2024.\nProgram Prior Authorization/Medical Necessity – Vowst (fecal microbiota\nspores, live-brpk)\nChange Control\nDate Change\n7/2023 New program.\n12/2023 Updated criteria to lower the number of required recurrent CDI.\nUpdated antibiotic course requirement. Added requirement of failure,\ncontraindication, or intolerance to Rebyota.\n12/2024 Annual review. Updated reference.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}